Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
      • Neuroimmunology: To Sense and Protect
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells

Ciriaco A. Piccirillo and Ethan M. Shevach
J Immunol August 1, 2001, 167 (3) 1137-1140; DOI: https://doi.org/10.4049/jimmunol.167.3.1137
Ciriaco A. Piccirillo
Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan M. Shevach
Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

CD4+CD25+ regulatory T cells inhibit organ-specific autoimmune diseases induced by CD4+CD25− T cells and are potent suppressors of CD4+CD25− T cell activation in vitro. We demonstrate that CD4+CD25+ T cells also suppress both proliferation and IFN-γ production by CD8+ T cells induced either by polyclonal or Ag-specific stimuli. CD4+CD25+ T cells inhibit the activation of CD8+ responders by inhibiting both IL-2 production and up-regulation of IL-2Rα-chain (CD25) expression. Suppression is mediated via a T-T interaction as activated CD4+CD25+ T cells suppress the responses of TCR-transgenic CD8+ T cells stimulated with soluble peptide-MHC class I tetramers in the complete absence of APC. These results broaden the immunoregulatory role played by CD4+CD25+ T cells in the prevention of autoimmune diseases, but also raise the possibility that they may hinder the induction of effector CD8+ T cells to tumor or foreign Ags.

Studies in a number of experimental models have demonstrated the existence of regulatory T cell populations that prevent the activation of autoreactive T cells (1, 2, 3). The most useful marker to date for identification of regulatory T cells is the CD25 (IL-2Rα-chain) Ag that is present on 5–10% of CD4+ T cells in normal animals (4, 5, 6, 7, 8). The functional properties of murine CD4+CD25+ T cells have been extensively studied in vitro. They demonstrate profound anergy to stimulation via their TCR, and this anergic state cannot be reversed by costimulation with anti-CD28 (9, 10). More importantly, when CD4+CD25+ T cells are cocultured with CD4+CD25− T cells, they induced profound suppression of T cell activation by down-regulating IL-2 production in the responding CD4+CD25− T cells (10). The suppressive activity of the CD4+CD25+ T cells requires that they be activated via their TCR and is cell contact dependent but cytokine independent (10, 11).

The mechanism by which CD4+CD25+ T cells mediate their suppressive effects is poorly understood. The physiologic ligand recognized by their TCR is unknown, and considerable controversy exists as to their cellular target. Thornton and Shevach (12) have demonstrated that the suppressors do not modulate APC function, whereas other laboratories have raised the possibility that they act by suppressing APC function (13) or by competing for APC-derived costimulatory signals (9). The potential suppressive activity of CD4+CD25+ T cells on non-CD4+ responder cells has not been studied in detail. Here, we demonstrate that CD4+CD25+ T cells suppress CD8+ T cell proliferation and IFN-γ production induced by polyclonal or Ag-specific stimuli. In addition, the effects of the CD4+CD25+ T cells on CD8+ cells are more complex than their effects on CD4+CD25− responders, because they suppress both IL-2 production and CD25 expression. Finally, we made use of peptide-MHC tetramers to stimulate CD8+ responders in a two-cell suppressor assay system to formally demonstrate that CD4+CD25+ cells mediate their suppressor function via a T-T cell interaction and in the absence of APC.

Materials and Methods

Mice

Female C57BL/6 and BALB/c mice were obtained from the National Cancer Institute (Frederick, MD). OT-I (specific for OVA257–264 peptide), F5 (specific for nucleoprotein (NP)366–374 influenza peptide), and P14 (specific for lymphocytic choriomeningitis virus (LCMV) gp33–41 peptide) CD8+ TCR-transgenic (Tg) mice were obtained from Taconic Farms (Germantown, NY). All mice used were 6–12 wk of age.

The mAbs

The following Abs were used for flow cytometry experiments: biotin-anti-CD25 (7D4 clone), FITC-streptavidin, PE-anti-CD4, PE-anti-CD8, FITC-anti-CD25, FITC-anti-CD69, and purified anti-CD3ε (2C11), all of which were purchased from BD PharMingen (San Diego, CA).

Peptides

OT-I OVA257–264, F5 NP366–374, and LCMV gp33–41 peptides were provided by R. Germain and J. Yewdell (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD). Peptides were synthesized and purified by the Laboratory of Molecular Structure Peptide Synthesis Laboratory (National Institute of Allergy and Infectious Diseases, National Institutes of Health).

Tetramers

MHC class I H-2Kb-OVA257–264 tetramer solutions were prepared at the National Institute of Allergy and Infectious Diseases tetramer facility.

Cell purification and culture

CD4+CD25+ T cells were isolated on a FACStar cell sorter (BD Biosciences, San Jose, CA) as described previously (10). The purity of the final CD4+CD25+ preparation was typically >95%. T-depleted spleen cells (10; TdS) were irradiated at 3000 rad and pulsed for 30 min at 37°C with an appropriate peptide. Activated CD4+CD25+ cells were prepared as previously described (12). Briefly, cell-sorted CD4+CD25+ cells were cultured with irradiated APC (1:1 ratio), anti-CD3 (0.5 μg/ml), and human IL-2 (5 ng/ml, 100 U/ml) for 72 h and were then split and maintained in IL-2 medium for ∼7–14 days. CD8+ T cells were purified either by negative (depletion of B220-, CD4-, and I-Ab-positive cells) or positive selection (using CD8α magnetic beads) on the AutoMACS magnetic separation system (Miltenyi Biotec, Auburn, CA). For experiments involving tetramer stimulation, OT-I CD8+ T cells were FACS purified using Abs against Thy1.2 and CD8α molecules, with final purities of >99%.

Proliferation assays

Proliferation assays were performed by culturing CD8+ T cells (5 × 104) in flat-bottom microtiter plates (0.2 ml) with peptide-pulsed APC (1–2 × 105) and resting or activated CD4+CD25+ or CD4+CD25− T cells for 72 h at 37°C in complete medium (10). Human rIL-2 was purchased from Peprotech (Rocky Hill, NJ). Cell cultures were pulsed with [3H]TdR for the last 8 h. All data represent the average cpm of triplicate determinations. All proliferation experiments were repeated at least three times.

For cytokine production, supernatants were taken at 72 h, and the production of IFN-γ was measured using an ELISA kit (R&D Systems, Minneapolis, MN).

Flow cytometry

Cells were collected and stained with PE-CD8α and FITC-CD69 or FITC-CD25 and analyzed with a FACScan flow cytometer (BD Biosciences).

Results and Discussion

When freshly explanted CD4+CD25+ T cells from normal mice were cocultured with F5 TCR-Tg CD8+ T cells, significant cell-dose-dependent suppression of proliferation was observed with soluble anti-CD3 as the stimulus in the presence of APC (Fig. 1⇓A). When the TCR-Tg cells were stimulated with specific peptide, no inhibition of proliferation was observed (data not shown). When activated CD4+CD25+ T cells from normal mice were used, marked suppression of proliferation of F5 CD8+ TCR-Tg T cells was observed with peptide stimulation (Fig. 1⇓C). This finding confirms previous studies (12) using CD4+ T cells as responders in which the CD4+CD25+ T cells required activation via their TCR to manifest suppressor function, but following activation, suppressor effector function was Ag-nonspecific and did not require restimulation of the suppressors via their TCR.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

CD4+CD25+ T cells suppress CD8+ T cell proliferation and effector function. Tg F5 CD8+ T cells (5 × 104) were stimulated with anti-CD3 and TdS (2 × 105; A and B) or NP366–374 peptide-pulsed TdS (2 × 105; C and D) and in the presence of either freshly isolated (A and B) or activated (C and D) CD4+CD25+ (▪) or CD4+CD25− (□) T cells. Proliferation (A and C) and IFN-γ production (B and D) were measured. Results from a representative experiment are shown.

Because CD8+ T cells will produce significant amounts of IFN-γ in the absence of previous priming, we next studied the effects of CD4+CD25+ T cells on the capacity of CD8+ T cells to produce IFN-γ. Freshly explanted CD4+CD25+ T cells readily suppressed IFN-γ production by CD8+ T cells stimulated with anti-CD3 (Fig. 1⇑B), and activated CD4+CD25+ T cells suppressed IFN-γ production when the CD8+ T cells were stimulated with specific peptide (Fig. 1⇑D). We have consistently shown >50% suppression of both proliferation and IFN-γ secretion at a CD25+:CD8 ratio of 1:2, and >75% suppression at a 1:1 cell ratio. CD4+CD25+ T cells (Fig. 1⇑, A and C) cultured alone do not proliferate and do not secrete IFN-γ (data not shown). CD4+CD25− T cells (Fig. 1⇑C) cultured in the absence of CD8+ T cells do not produce IFN-γ (data not shown).

IL-2 will reverse suppression when CD4+CD25+ suppressors are cocultured with CD4+CD25− responders. It has been proposed that IL-2 can directly act on the suppressors and reverse their anergic phenotype and consequently disable their suppressive capability (14). Alternatively, the addition of exogenous IL-2 may simply be circumventing the block in IL-2 production induced in the responders by the CD4+CD25+ suppressors. When fresh CD4+CD25+ T cells (Fig. 2⇓A) or activated CD4+CD25+ T cells (Fig. 2⇓B) were cocultured with OT-I CD8+ T cells, significant suppression of proliferation (∼60%) and IFN-γ production (Fig. 2⇓C) was observed with soluble anti-CD3 or peptide stimulation. Suppression was not reversed by the addition of exogenous IL-2 at all suppressor:responder ratios or by enhancement of endogenous IL-2 production by the addition of anti-CD28 (data not shown). Increasing the amount of IL-2 added to the cocultures to 100 U/ml also had no effect. It should be noted that the proliferative response of CD4+CD25+ T cells to IL-2 is modest when compared with activated CD4+CD25− T cells. Thus, the contribution of the activated CD4+CD25+ T cells to the proliferative responses in the cocultures performed in the presence of IL-2 is also minimal but may contribute some residual proliferation to the culture. The hypothesis (9) that IL-2 abrogates suppressor function is not supported by our studies on CD8+ responders because suppression is clearly maintained in the presence of IL-2.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

IL-2 does not reverse CD4+CD25+-mediated suppression. A, Tg OT-I CD8+ T cells (5 × 104) were stimulated with anti-CD3 (0.5 μg/ml) and TdS (2 × 105) and either freshly isolated CD4+CD25+ (circles) or CD4+CD25− (squares) T cells in the presence (filled symbols) or absence (open symbols) of exogenous IL-2 (100 U/ml). B, Tg OT-I CD8+ T cells (5 × 104) were stimulated with OVA257–264 peptide-pulsed TdS (2 × 105) and either activated CD4+CD25+ (circles) or CD4+CD25− (squares) T cells in the presence (filled symbols) or absence (open symbols) of exogenous IL-2 (100 U/ml). Proliferation was assayed as in Fig. 1⇑C. Supernatants from B were collected at 72 h, and IFN-γ ELISA was performed.

We next examined the expression of CD25 on F5 CD8+ T cells stimulated either in the presence or absence of CD4+CD25+ T cells. Following 6 h of stimulation with peptide-pulsed APC, up-regulation of CD25 expression on the F5 CD8+ T cell responders was similar in presence or absence of CD4+CD25+ T cells (Fig. 3⇓A). However, no further up-regulation of CD25 on the CD8+ responders was seen in the CD4+CD25+/CD8+ cocultures (Fig. 3⇓A). The expression of CD69 was identical on CD8+ responders stimulated in the presence or absence of CD4+CD25+ cells at both time points tested (Fig. 3⇓A). In multiple (n = 5) experiments, addition of activated CD4+CD25+ T cells resulted in 73 ± 5% suppression of the induction of CD25 when the responding CD8+ T cells were assayed for CD25 expression following 24 h of stimulation. The addition of exogenous IL-2 (100 U/ml) also failed to restore the level of CD25 expression on suppressed responders to levels seen on responders cultured alone (Fig. 3⇓B) or responders cultured with activated CD4+CD25− T cells (data not shown).

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

CD4+CD25+ regulatory T cells suppress IL-2Rα expression on responding CD8+ T cells, and IL-2 fails to rescue its expression. A, Tg F5 CD8+ T cells (5 × 105) were stimulated with NP366–374 peptide-pulsed TdS (2 × 106) either alone (filled line) or with activated CD4+CD25+ T cells (5 × 105; solid line). FACS analysis for CD25 and CD69 was performed at 6 and 24 h and compared with unstimulated CD8+ T cells (dotted line). B, Tg P14 CD8+ T cells (5 × 105) were stimulated with LCMV gp33–41 peptide-pulsed TdS (2 × 106) either alone (solid line) or with activated CD4+CD25+ T cells (5 × 105; dotted line) in the presence of exogenous IL-2 (100 U/ml). FACS analysis for CD25 was performed at 24 h and compared with unstimulated CD8+ T cells (filled line). All histograms were gated on CD8+ T cells. CD8+ T cells stimulated in the presence of activated CD4+CD25− cells displayed CD25 and CD69 expression levels indistinguishable to those observed when CD8+ T cells were cultured alone (data not shown).

Soluble tetramer stimulation of OT-I CD8+ T cells resulted in robust T cell proliferation (Fig. 4⇓A) and IFN-γ production (Fig. 4⇓B), confirming previous studies (15, 16, 17) showing that CD8+ T cells can be efficiently activated in the absence of APC and APC-derived costimulatory signals. CD8+ T cells from normal C57BL/6 mice did not proliferate at any tetramer concentration (Fig. 4⇓A), nor did an irrelevant soluble tetramer (H-2Db/CEA antigenic peptide) preparation induce proliferation (data not shown) or IFN-γ production (Fig. 4⇓B). To directly assess whether CD4+CD25+ T cells suppress CD8+ T cell responders by modulating APC function or by direct T-T contact, we stimulated highly purified OT-I CD8+ T cells (>99% pure) with soluble MHC I H-2Kb-OVA257–264 tetramers, in the presence or absence of titrated numbers of CD4+CD25+ T cells. Marked suppression of both proliferation and IFN-γ production was seen in the presence of CD4+CD25+ T cells, but not CD4+CD25− cells, even at low CD4+CD25+:CD8+ ratios (Fig. 4⇓, C and D). Taken together, the results from this two-cell system conclusively demonstrate that CD4+CD25+-mediated suppression occurs via a T-T cell interaction, and the APC is not directly required for the delivery of the suppressive signal to responding CD8+ T cells.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Suppression mediated by CD4+CD25+ T cells is APC-independent. A, Tg (OT-I) and non-Tg (wild-type B6) CD8+ T cells (5 × 104) were stimulated with varying concentrations of soluble MHC I H-2Kb-OVA257–264 tetramers. Proliferation was measured as in Fig. 1⇑. B, Culture supernatants were harvested at 48 h, and IFN-γ ELISA was performed. C, Tg OT-I CD8+ T cells (5 × 104) were stimulated with soluble MHC I H-2Kb-OVA257–264 tetramers (0.5 μg/ml) and titrated numbers of activated CD4+CD25+ (▪) or CD4+CD25− (□) T cells, and proliferation was assayed. D, Supernatants were collected at 72 h, and IFN-γ ELISA was performed.

CD8+ T cells may contribute to the immunopathogenesis of many autoimmune diseases (18, 19, 20, 21). Therefore, it is desirable that regulatory T cells be able to control autoreactive CD8+ T cells as well as CD4+ T cells. Most of the effects of regulatory CD4+CD25+ T cells on CD8+ responders were similar to those seen with CD4+ responders. However, several important differences should be noted. First, in addition to T cell proliferation, the capacity of fresh CD8+ T cells to manifest effector function such as the production of IFN-γ was also suppressed. Second, whereas CD4+CD25+ T cells inhibit the activation of CD4+ responders by primarily blocking IL-2 production, CD4+CD25+ T cells regulate CD8+ T cell responses both by blocking IL-2 production as well as by lowering responsiveness to exogenous IL-2 and thereby potentially disrupting CD4 help for CD8+ T cells. Finally, CD4+CD25+ T cells can inhibit T cell activation by directly acting on responder CD8+ T cells in the absence of APC. However, this result does not exclude the possibility that CD4+CD25+ T cells might also exert inhibitory/deactivating effects on APC or use the APC surface as a platform on which the suppressor cells physically interact with CD4+ or CD8+ effectors in vivo.

Although immunoregulatory CD4+CD25+ cells function beneficially in vivo to protect the host against the development of autoimmunity, they may simultaneously prevent the host from mounting an immune response to autoantigens such as tumor Ags. Because IL-2 responsiveness by CD8+ T cells is a critical factor for cytokine production (IFN-γ) and cytolytic activity (22, 23), our demonstration that CD4+CD25+ T cells down-regulate both IL-2 production and CD25 expression on CD8+ T cells may represent a significant impediment to the use of tumor or viral vaccines. Indeed, deletion of CD4+CD25+ T cells before the use of such vaccines may be needed for optimal immunotherapy.

Footnotes

  • ↵1 Address correspondence and reprint requests to Dr. Ethan M. Shevach, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N311, 10 Center Drive, Bethesda, Maryland 20892-1892. E-mail address: ems1{at}mail.nih.gov

  • 2 Abbreviations used in this paper: NP, nucleoprotein; LCMV, lymphocytic choriomeningitis virus; Tg, transgenic; TdS, T-depleted spleen cells.

  • Received April 30, 2001.
  • Accepted June 4, 2001.
  • Copyright © 2001 by The American Association of Immunologists

References

  1. ↵
    Shevach, E. M.. 2000. Suppressor T cells: rebirth, function and homeostasis. Curr. Biol. 10: R572
    OpenUrlCrossRefPubMed
  2. ↵
    Fowell, D., D. Mason. 1993. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes: characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J. Exp. Med. 177: 627
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Sakaguchi, S.. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455
    OpenUrlCrossRefPubMed
  4. ↵
    Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Powrie, F., M. W. Leach, S. Mauze, L. B. Caddle, R. L. Coffman. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5: 1461
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Sakaguchi, S., M. Toda, M. Asano, M. Itoh, S. S. Morse, N. Sakaguchi. 1996. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J. Autoimmun. 9: 211
    OpenUrlCrossRefPubMed
  7. ↵
    Asano, M., M. Toda, N. Sakaguchi, S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184: 387
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, J. A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431
    OpenUrlCrossRefPubMed
  9. ↵
    Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu, S. Sakaguchi. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10: 1969
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Thornton, A. M., E. M. Shevach. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188: 287
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Takahashi, T., T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. W. Mak, S. Sakaguchi. 2000. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192: 303
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Thornton, A. M., E. M. Shevach. 2000. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164: 183
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Cederbom, L., H. Hall, F. Ivars. 2000. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30: 1538
    OpenUrlCrossRefPubMed
  14. ↵
    Itoh, M., T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka, S. Sakaguchi. 1999. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162: 5317
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Wang, B., R. Maile, R. Greenwood, E. J. Collins, J. A. Frelinger. 2000. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells. J. Immunol. 164: 1216
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Lu, P., Y. L. Wang, P. S. Linsley. 1997. Regulation of self-tolerance by CD80/CD86 interactions. Curr. Opin. Immunol. 9: 858
    OpenUrlCrossRefPubMed
  17. ↵
    Sepulveda, H., A. Cerwenka, T. Morgan, R. W. Dutton. 1999. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J. Immunol. 163: 1133
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Vizler, C., N. Bercovici, A. Cornet, C. Cambouris, R. S. Liblau. 1999. Role of autoreactive CD8+ T cells in organ-specific autoimmune diseases: insight from transgenic mouse models. Immunol. Rev. 169: 81
    OpenUrlCrossRefPubMed
  19. ↵
    Herrera, P. L., D. M. Harlan, P. Vassalli. 2000. A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc. Natl. Acad. Sci. USA 97: 279
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Wong, F. S., I. Visintin, L. Wen, R. A. Flavell, C. A. Janeway. 1996. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183: 67
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Wong, F. S., C. A. Janeway. 1997. The role of CD4 and CD8 T cells in type I diabetes in the NOD mouse. Res. Immunol. 148: 327
    OpenUrlCrossRefPubMed
  22. ↵
    Sad, S., L. Krishnan. 1999. Cytokine deprivation of naive CD8+ T cells promotes minimal cell cycling but maximal cytokine synthesis and autonomous proliferation subsequently: a mechanism of self-regulation. J. Immunol. 163: 2443
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Mosmann, T. R., S. Sad, L. Krishnan, T. G. Wegmann, L. J. Guilbert, M. Belosevic. 1995. Differentiation of subsets of CD4+ and CD8+ T cells. Ciba Found. Symp. 195: 42
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 167 (3)
The Journal of Immunology
Vol. 167, Issue 3
1 Aug 2001
  • Table of Contents
  • About the Cover
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells
Ciriaco A. Piccirillo, Ethan M. Shevach
The Journal of Immunology August 1, 2001, 167 (3) 1137-1140; DOI: 10.4049/jimmunol.167.3.1137

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells
Ciriaco A. Piccirillo, Ethan M. Shevach
The Journal of Immunology August 1, 2001, 167 (3) 1137-1140; DOI: 10.4049/jimmunol.167.3.1137
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutting Edge: Reduced Adenosine-to-Inosine Editing of Endogenous Alu RNAs in Severe COVID-19 Disease
  • Cutting Edge: EPHB2 Is a Coreceptor for Fungal Recognition and Phosphorylation of Syk in the Dectin-1 Signaling Pathway
  • Cutting Edge: Hypoxia-Induced Ubc9 Promoter Hypermethylation Regulates IL-17 Expression in Ulcerative Colitis
Show more CUTTING EDGE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606